Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Discovery of Mutated MUC3A Gene As a Novel Transcription Factor Exclusively Associated with Accelerated Phase Chronic Myeloid Leukemia: Hunt for Common Biomarker of Fatal CML Progression

Sameen Shahid, Muhammad Sabar, Abid Jamil, Muhammad Abbas Khokar, Muhammad Absar, Mudassar Iqbal, Masood A. Shammas, Giuseppe Saglio, Sulman Basit, Sibtain Afzal, Khushnooda Ramzan, Aamer Aleem, Amer Mahmood, Nawaf Alanzazi, Muhammad Javed Asif, Mahmood Rasool, Ahmad Khalid, Zafar Iqbal

Blood (2023) 142 (Supplement 1): 7429.

https://doi.org/10.1182/blood-2023-185547

Published: 2023

Journal Articles

Next-Generation Sequencing Identifies a Previously Uncharacterized Gene ANKRD36 As a Common Biomarker for Blast Crisis Chronic Myeloid Leukemia: Molecular and Protein Bio-Modeling Studies

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-143068

Published: 2020

Journal Articles

Investigations on Novel Gene Variants Associated with Longterm Response to Tyrosine Kinase Inhibitors (TKIs) in Chronic Myeloid Leukemia: Implication in TKI-Cessation Clinical Trails

Zafar Iqbal, BSc, MSc, PhD, Muhammad Absar, BSc, MSc, PhD, Abid Jameel, MD PhD, Tanveer Akhtar, PhD, Sulman Basit, PhDMSc, Aamer Mahmood, PhD, Aamir Aleem, MBBS FRCP, Nawaf Alanazi, MBBS FRCPC, Ullah Anhar, Naila Batool Khalid, Sibtain Afzal, Jamil Amjad Hashmi, Afia M Akram, PhD, Khushnooda Ramzan, PhD, Mahmood Rasool, Muhammad Hasaan Aziz, Muhammad Farooq Sabar, PhD, Mudassar Iqbal, MDMS, Ahmad Mukhtar Khalid, PhD

Blood (2019) 134 (Supplement_1): 2939.

https://doi.org/10.1182/blood-2019-125518

Published: 2019

Journal Articles

Disovery of Novel Mutations Exclusively Shared By Accelerated and Blast Crisis Phase CML Patients Using Whole Exome Sequencing:Implication in Hunt for Common Biomarker /Drug Target of CML Progression

Zafar Iqbal, MPhil PhD, Salman Basit, PhD, Abid Jamil, MDPhD, Muhammad Absar, Anhar Ullah, MS, Sibtain Afzal, Aamer Mahmood, PhD, Khushnooda Ramzan, PhD, Aamir Aleem, Jamil Amjad Hashmi, Noor Rehman, Khalid Aljamaan, Saleh Aloraibi, Giuseppe Saglio, MD PhD, Nawaf Alanazi, Mudassar Iqbal, MDMS, Tanveer Akhtar

Blood (2017) 130 (Supplement 1): 2886.

https://doi.org/10.1182/blood.V130.Suppl_1.2886.2886

Published: 2017

Journal Articles

Low Representation of ETV6-RUNX1 Fusion Oncogene in Pediatric Acute Lymphoblastic Leukemia Patients from Saudi Arabia and Strong Association with Clinical Response to Day-14 of Remission Induction Therapy

Khalid Aljamaan, MD, Talal Khalid Aljumah, MBBS, Saleh Aloraibi, PhD, Muhammad Absar, MSc PhD, Giuseppe Saglio, MD, Zafar Iqbal, MPhil PhD

Blood (2015) 126 (23): 4987.

https://doi.org/10.1182/blood.V126.23.4987.4987

Published: 2015

Journal Articles

Detection of Compound BCR-ABL Mutations in TKI Resistant CML Patients Including a Novel K245N Mutation Associated with Primary Nilotinib Resistance By Employing a Newly Developed Cost Effective BCR-ABL Sequencing Protocol

Blood (2014) 124 (21): 1810.

https://doi.org/10.1182/blood.V124.21.1810.1810

Published: 2014

Journal Articles

High Frequency Of BCR-ABL/t(22;9) Translocation As Detected By RT-PCR and Interphase FISH In Pediatric B-Cell ALL Patients Identifies The Need For Immediate Inclusion Of Tyrosine Kinase Inhibitors In Pediatric ALL Treatment Protocols

Zafar Iqbal, MPhil PhD Post-doctorate, Tashfin Awan, MSc PhD, Tanveer Akhtar, MSc, PhD, Aleem Aamer, MBBS MRCP FRCPath, Noreen Sabir, MSc PhD, Muhammad Absar, MSc, Iqbal Mudassar, MD MS, Ahmad Mukhtar Khalid, MSc, PhD, Giuseppe Saglio, MD, Mahmood Rasool, Akhtar Hussain, BS MPhil

Blood (2013) 122 (21): 3908.

https://doi.org/10.1182/blood.V122.21.3908.3908

Published: 2013

Journal Articles

Detection of Five Common Fusion Oncogenes in Pakistani Children with Acute Lymphoblastic Leukemia and Their Association with Clinical Pattern and Treatment Outcome

Blood (2012) 120 (21): 5124.

https://doi.org/10.1182/blood.V120.21.5124.5124

Published: 2012

Journal Articles

Characterization of Common Fusion Oncogenes As Prognostic Molecular Identities in Adult Acute Lymphoblastic Leukemia Identifies the Need for Genetic Testing At Presentation, Molecular Prognostication and Differential Treatment

Blood (2012) 120 (21): 5115.

https://doi.org/10.1182/blood.V120.21.5115.5115

Published: 2012

NARROW

Discovery of Mutated MUC3A Gene As a Novel Transcription Factor Exclusively Associated with Accelerated Phase Chronic Myeloid Leukemia: Hunt for Common Biomarker of Fatal CML Progression

Next-Generation Sequencing Identifies a Previously Uncharacterized Gene ANKRD36 As a Common Biomarker for Blast Crisis Chronic Myeloid Leukemia: Molecular and Protein Bio-Modeling Studies

Investigations on Novel Gene Variants Associated with Longterm Response to Tyrosine Kinase Inhibitors (TKIs) in Chronic Myeloid Leukemia: Implication in TKI-Cessation Clinical Trails

Disovery of Novel Mutations Exclusively Shared By Accelerated and Blast Crisis Phase CML Patients Using Whole Exome Sequencing:Implication in Hunt for Common Biomarker /Drug Target of CML Progression

Low Representation of ETV6-RUNX1 Fusion Oncogene in Pediatric Acute Lymphoblastic Leukemia Patients from Saudi Arabia and Strong Association with Clinical Response to Day-14 of Remission Induction Therapy

Detection of Compound BCR-ABL Mutations in TKI Resistant CML Patients Including a Novel K245N Mutation Associated with Primary Nilotinib Resistance By Employing a Newly Developed Cost Effective BCR-ABL Sequencing Protocol

High Frequency Of BCR-ABL/t(22;9) Translocation As Detected By RT-PCR and Interphase FISH In Pediatric B-Cell ALL Patients Identifies The Need For Immediate Inclusion Of Tyrosine Kinase Inhibitors In Pediatric ALL Treatment Protocols

Detection of Five Common Fusion Oncogenes in Pakistani Children with Acute Lymphoblastic Leukemia and Their Association with Clinical Pattern and Treatment Outcome

Characterization of Common Fusion Oncogenes As Prognostic Molecular Identities in Adult Acute Lymphoblastic Leukemia Identifies the Need for Genetic Testing At Presentation, Molecular Prognostication and Differential Treatment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only